{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:06:06Z","timestamp":1790960766226,"version":"4.1.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Acute exacerbation (AE) is a devastating phenomenon and reported to be complicated with systemic autoimmune disease-associated interstitial lung disease (ILD). The aim of this study was to investigate the incidence and prognosis of AE of systemic autoimmune disease-ILD and clarify relevant clinical information predictive of these outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>This study was designed as a systematic review and meta-analysis. A primary study except for a case report, which reported the incidence and\/or prognosis of AE of systemic autoimmune disease-ILD, was eligible for the review. Electronic databases such as Medline and EMBASE were searched from 2002 through 23 February 2020. Two reviewers independently selected eligible reports and extracted relevant data. Risk of bias of individual studies was assessed similarly. The incidence and prognosis of the disease were analysed qualitatively. Univariate results of risk and prognostic factors were combined if feasible.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of a total of 2662 records, 24 studies were eligible. A total of 420 subjects with 45.7% of men developed AE of systemic autoimmune disease-ILD and the two major underlying systemic autoimmune diseases were rheumatoid arthritis (34.2%) and polymyositis\/dermatomyositis (31.9%). The frequency ranged from 4.3 to 32.9% with the incident rate being 3.19 and 5.77 per 100 patient-years and all-cause mortality was between 30.0 and 58.3% at 90\u00a0days. Age at initial presentation was significantly associated with the development of AE of systemic autoimmune disease-ILD with an HR of 1.22 (95%CI 1.05\u20131.50) while a percentage of predicted diffusing capacity of the lung for carbon monoxide (%DLCO) was also significantly associated with the development of the disease with an HR of 0.95 (95%CI 0.90\u20131.00) and an OR of 0.97 (95%CI 0.95\u20130.99). Partial pressure of arterial oxygen\/fraction of inspired oxygen ratio (PaO<jats:sub>2<\/jats:sub>\/FiO<jats:sub>2<\/jats:sub>) at AE was significantly associated with all-cause mortality of AE of systemic autoimmune disease-ILD with an HR of 0.99 (95%CI 0.98\u20130.99).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>AE of systemic autoimmune disease-ILD was not uncommon and demonstrated dismal prognosis. Age at initial presentation and %DLCO were deemed as risk factors while PaO<jats:sub>2<\/jats:sub>\/FiO<jats:sub>2<\/jats:sub> at AE was considered as a prognostic factor of the disease.<\/jats:p>\n                <jats:p><jats:italic>Registration<\/jats:italic>\u00a0CRD42019138941.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-021-01502-w","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T17:02:52Z","timestamp":1620234172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A systematic review of the incidence, risk factors and prognosis of acute exacerbation of systemic autoimmune disease-associated interstitial lung disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Hiroyuki","family":"Kamiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogee Mer","family":"Panlaqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"1502_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/resp.12551","volume":"20","author":"GC Tabaj","year":"2015","unstructured":"Tabaj GC, Fernandez CF, Sabbagh E, et al. Histopathology of the idiopathic interstitial pneumonias (IIP): a review. Respirology. 2015;20:873\u201383.","journal-title":"Respirology"},{"key":"1502_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1378\/chest.15-1145","volume":"149","author":"Y Hu","year":"2016","unstructured":"Hu Y, Wang LS, Wei YR, et al. Clinical characteristics of connective tissue disease-associated interstitial lung disease in 1044 Chinese patients. Chest. 2016;149:201\u20138.","journal-title":"Chest"},{"key":"1502_CR3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","volume":"7","author":"S Skeoch","year":"2018","unstructured":"Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018;7:356.","journal-title":"J Clin Med"},{"key":"1502_CR4","first-page":"193","volume":"21","author":"M Gulati","year":"2015","unstructured":"Gulati M, Redlich CA. Asbestosis and environmental causes of usual interstitial pneumonia. Curr Opin Pulm Med. 2015;21:193\u2013200.","journal-title":"Curr Opin Pulm Med"},{"key":"1502_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(12)61079-4","volume":"380","author":"A Fischer","year":"2012","unstructured":"Fischer A, Du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380:689\u201398.","journal-title":"Lancet"},{"key":"1502_CR6","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","volume":"53","author":"CA Kelly","year":"2014","unstructured":"Kelly CA, Saravanan V, Nisar M. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics-a large multicentre UK study. Rheumatology. 2014;53:1676\u201382.","journal-title":"Rheumatology"},{"key":"1502_CR7","doi-asserted-by":"publisher","first-page":"102447","DOI":"10.1016\/j.autrev.2019.102447","volume":"19","author":"G Sambataro","year":"2020","unstructured":"Sambataro G, Ferro F, Orlandi M, et al. Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sj\u00f6gren\u2019s syndrome: a systematic review from the Italian Society of Rheumatology. Autoimmun Rev. 2020;19:102447.","journal-title":"Autoimmun Rev."},{"key":"1502_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/1479972310393758","volume":"8","author":"A De Lauretis","year":"2011","unstructured":"De Lauretis A, Veeraraghavan S, Renzoni E. Connective tissue disease-associated interstitial lung disease: how does it differ from IPF? how should the clinical approach differ? Chron Respir Dis. 2011;8:53\u201382.","journal-title":"Chron Respir Dis"},{"key":"1502_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1164\/rccm.200607-912OC","volume":"175","author":"JH Park","year":"2007","unstructured":"Park JH, Kim DS, Park I-N, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175:705\u201311.","journal-title":"Am J Respir Crit Care Med"},{"key":"1502_CR10","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1183\/09031936.00019210","volume":"37","author":"Y Tsuchiya","year":"2011","unstructured":"Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J. 2011;37:1411\u20137.","journal-title":"Eur Respir J"},{"key":"1502_CR11","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1378\/chest.103.6.1808","volume":"103","author":"Y Kondoh","year":"1993","unstructured":"Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993;103:1808\u201312.","journal-title":"Chest"},{"key":"1502_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1365-2559.2010.03650.x","volume":"58","author":"A Churg","year":"2011","unstructured":"Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. Histopathology. 2011;58:525\u201330.","journal-title":"Histopathology"},{"key":"1502_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1164\/rccm.200702-220OC","volume":"176","author":"BW Kinder","year":"2007","unstructured":"Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007;176:691\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1502_CR14","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"key":"1502_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431\u201340.","journal-title":"Am J Respir Crit Care Med"},{"key":"1502_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194:265\u201375.","journal-title":"Am J Respir Crit Care Med."},{"key":"1502_CR17","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1378\/chest.12-0741","volume":"143","author":"R Vij","year":"2013","unstructured":"Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143:814\u201324.","journal-title":"Chest"},{"key":"1502_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139.","journal-title":"Ann Intern Med"},{"key":"1502_CR19","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283:2008\u201312.","journal-title":"JAMA"},{"key":"1502_CR20","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1502_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1502_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"key":"1502_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194:265\u201375.","journal-title":"Am J Respir Crit Care Med"},{"key":"1502_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2559.2004.01896.x","volume":"44","author":"D Tansey","year":"2004","unstructured":"Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44:585\u201396.","journal-title":"Histopathology"},{"key":"1502_CR25","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"A Fischer","year":"2015","unstructured":"Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46:976\u201387.","journal-title":"Eur Respir J"},{"key":"1502_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","author":"American Thoracic Society","year":"2002","unstructured":"American Thoracic Society. American Thoracic Society\/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165:277\u2013304.","journal-title":"Am J Respir Crit Care Med"},{"key":"1502_CR27","doi-asserted-by":"publisher","first-page":"e0138237","DOI":"10.1371\/journal.pone.0138237","volume":"10","author":"NR Haddaway","year":"2015","unstructured":"Haddaway NR, Collins AM, Coughlin D, et al. The role of google scholar in evidence reviews and its applicability to grey literature searching. PLoS ONE. 2015;10:e0138237.","journal-title":"PLoS ONE"},{"key":"1502_CR28","doi-asserted-by":"publisher","first-page":"e020862","DOI":"10.1136\/bmjopen-2017-020862","volume":"8","author":"H Kamiya","year":"2018","unstructured":"Kamiya H, Panlaqui OM. Prognostic significance of autoantibodies for idiopathic pulmonary fibrosis: protocol for a systematic review. BMJ Open. 2018;8:e020862.","journal-title":"BMJ Open"},{"key":"1502_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","volume":"144","author":"JA Hayden","year":"2006","unstructured":"Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144:427\u201337.","journal-title":"Ann Intern Med"},{"key":"1502_CR30","doi-asserted-by":"publisher","first-page":"b375","DOI":"10.1136\/bmj.b375","volume":"338","author":"KG Moons","year":"2009","unstructured":"Moons KG, Royston P, Vergouwe Y, et al. Prognosis and prognostic research: what, why, and how? BMJ. 2009;338:b375.","journal-title":"BMJ"},{"key":"1502_CR31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0895-4356(02)00443-2","volume":"55","author":"MJ Symons","year":"2002","unstructured":"Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. J Clin Epidemiol. 2002;55:893\u20139.","journal-title":"J Clin Epidemiol"},{"key":"1502_CR32","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/0010-4809(88)90004-3","volume":"21","author":"JR Bock","year":"1988","unstructured":"Bock JR, Afifi AA. Estimation of probabilities using the logistic model in retrospective studies. Comput Biomed Res. 1988;21:449\u201370.","journal-title":"Comput Biomed Res"},{"key":"1502_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"1502_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"1502_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"1502_CR36","unstructured":"Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from: http:\/\/www.handbook.cochrane.org."},{"key":"1502_CR37","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","volume":"342","author":"RD Riley","year":"2011","unstructured":"Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.","journal-title":"BMJ"},{"key":"1502_CR38","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"1502_CR39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455\u201363.","journal-title":"Biometrics"},{"key":"1502_CR40","doi-asserted-by":"publisher","first-page":"h870","DOI":"10.1136\/bmj.h870","volume":"350","author":"A Iorio","year":"2015","unstructured":"Iorio A, Spencer FA, Falavigna M, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ. 2015;350:h870.","journal-title":"BMJ"},{"key":"1502_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1440-1843.2009.01666.x","volume":"15","author":"K Isobe","year":"2010","unstructured":"Isobe K, Hata Y, Sakamoto S, et al. Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology. 2010;15:88\u201392.","journal-title":"Respirology"},{"key":"1502_CR42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12890-019-0868-9","volume":"19","author":"JU Lim","year":"2019","unstructured":"Lim JU, Gil BM, Kang HS, et al. Interstitial pneumonia with autoimmune features show better survival and less exacerbations compared to idiopathic pulmonary fibrosis. BMC Pulm Med. 2019;19:120.","journal-title":"BMC Pulm Med"},{"key":"1502_CR43","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1378\/chest.07-0323","volume":"132","author":"IN Park","year":"2007","unstructured":"Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest. 2007;132:214\u201320.","journal-title":"Chest"},{"key":"1502_CR44","first-page":"103","volume":"30","author":"JW Song","year":"2013","unstructured":"Song JW, Lee HK, Lee CK, et al. Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30:103\u201312.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"1502_CR45","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/resp.13682","volume":"25","author":"A Suzuki","year":"2020","unstructured":"Suzuki A, Kondoh Y, Brown KK, et al. Acute exacerbations of fibrotic interstitial lung diseases. Respirology. 2020;25:525\u201334.","journal-title":"Respirology"},{"key":"1502_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000329893","volume":"83","author":"R Tachikawa","year":"2012","unstructured":"Tachikawa R, Tomii K, Ueda H, et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic. Respiration. 2012;83:20\u20137.","journal-title":"Respiration"},{"key":"1502_CR47","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1620\/tjem.239.297","volume":"239","author":"F Tomiyama","year":"2016","unstructured":"Tomiyama F, Watanabe R, Ishii T, et al. High prevalence of acute exacerbation of interstitial lung disease in Japanese patients with systemic sclerosis. Tohoku J Exp Med. 2016;239:297\u2013305.","journal-title":"Tohoku J Exp Med"},{"key":"1502_CR48","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00296-016-3478-3","volume":"36","author":"M Akiyama","year":"2016","unstructured":"Akiyama M, Kaneko Y, Yamaoka K, et al. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Rheumatol Int. 2016;36:881\u20139.","journal-title":"Rheumatol Int"},{"key":"1502_CR49","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12890-019-0960-1","volume":"19","author":"M Cao","year":"2019","unstructured":"Cao M, Sheng J, Qiu X, et al. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study. BMC Pulm Med. 2019;19:215.","journal-title":"BMC Pulm Med"},{"key":"1502_CR50","doi-asserted-by":"publisher","first-page":"147997231880947","DOI":"10.1177\/1479972318809476","volume":"16","author":"N Enomoto","year":"2019","unstructured":"Enomoto N, Oyama Y, Enomoto Y, et al. Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis. Chronic Respir Dis. 2019;16:1479972318809476.","journal-title":"Chronic Respir Dis"},{"key":"1502_CR51","doi-asserted-by":"publisher","first-page":"e003132","DOI":"10.1136\/bmjopen-2013-003132","volume":"3","author":"H Hozumi","year":"2013","unstructured":"Hozumi H, Nakamura Y, Johkoh T, et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open. 2013;3:e003132.","journal-title":"BMJ Open"},{"key":"1502_CR52","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/1753465817708950","volume":"11","author":"H Ichiyasu","year":"2017","unstructured":"Ichiyasu H, Horio Y, Masunaga A, et al. Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies. Ther Adv Respir Dis. 2017;11:261\u201375.","journal-title":"Ther Adv Respir Dis"},{"key":"1502_CR53","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.rmed.2017.05.009","volume":"128","author":"G Ishikawa","year":"2017","unstructured":"Ishikawa G, Acquah SO, Salvatore M, et al. Elevated serum D-dimer level is associated with an increased risk of acute exacerbation in interstitial lung disease. Respir Med. 2017;128:78\u201384.","journal-title":"Respir Med"},{"key":"1502_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fmed.2020.00012","volume":"7","author":"J Liang","year":"2020","unstructured":"Liang J, Cao H, Ke Y, et al. Acute exacerbation of interstitial lung disease in adult patients with idiopathic inflammatory myopathies: a retrospective case-control study. Front Med. 2020;7:12.","journal-title":"Front Med"},{"key":"1502_CR55","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.21037\/jtd.2019.03.28","volume":"11","author":"A Manfredi","year":"2019","unstructured":"Manfredi A, Sebastiani M, Cerri S, et al. Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. J Thorac Dis. 2019;11:1621\u20138.","journal-title":"J Thorac Dis"},{"key":"1502_CR56","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.resinv.2016.05.004","volume":"54","author":"M Okamoto","year":"2016","unstructured":"Okamoto M, Fujimoto K, Sadohara J, et al. A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease. Respir Investig. 2016;54:445\u201353.","journal-title":"Respir Investig"},{"key":"1502_CR57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3109\/14397595.2016.1173816","volume":"27","author":"M Ota","year":"2017","unstructured":"Ota M, Iwasaki Y, Harada H, et al. Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol. 2017;27:22\u20138.","journal-title":"Mod Rheumatol"},{"key":"1502_CR58","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1378\/chest.130.2.553","volume":"130","author":"JG Parambil","year":"2006","unstructured":"Parambil JG, Myers JL, Ryu JH. Diffuse alveolar damage: uncommon manifestation of pulmonary involvement in patients with connective tissue diseases. Chest. 2006;130:553\u20138.","journal-title":"Chest"},{"key":"1502_CR59","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/01.rti.0000213588.52343.13","volume":"22","author":"CIS Silva","year":"2007","unstructured":"Silva CIS, Muller NL, Fujimoto K, et al. Acute exacerbation of chronic interstitial pneumonia: high-resolution computed tomography and pathologic findings. J Thorac Imaging. 2007;22:221\u20139.","journal-title":"J Thorac Imaging"},{"key":"1502_CR60","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1111\/1756-185X.13666","volume":"22","author":"P Singh","year":"2019","unstructured":"Singh P, Thakur B, Mohapatra AK, et al. Clinical features and outcome of acute exacerbation in connective tissue disease-associated interstitial lung disease: a single-center study from India. Int J Rheum Dis. 2019;22:1741\u20135.","journal-title":"Int J Rheum Dis"},{"key":"1502_CR61","doi-asserted-by":"publisher","first-page":"e6617","DOI":"10.1097\/MD.0000000000006617","volume":"96","author":"Y Su","year":"2017","unstructured":"Su Y, Gu H, Weng D, et al. Association of serum levels of laminin, type IV collagen, procollagen III N-terminal peptide, and hyaluronic acid with the progression of interstitial lung disease. Medicine. 2017;96:e6617.","journal-title":"Medicine"},{"key":"1502_CR62","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.rmed.2008.12.019","volume":"103","author":"T Suda","year":"2009","unstructured":"Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med. 2009;103:846\u201353.","journal-title":"Respir Med"},{"key":"1502_CR63","doi-asserted-by":"publisher","first-page":"294","DOI":"10.2152\/jmi.63.294","volume":"63","author":"Y Toyoda","year":"2016","unstructured":"Toyoda Y, Hanibuchi M, Kishi J, et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease. J Med Invest. 2016;63:294\u20139.","journal-title":"J Med Invest"},{"key":"1502_CR64","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.21037\/jtd.2019.11.73","volume":"11","author":"H Yamakawa","year":"2019","unstructured":"Yamakawa H, Sato S, Tsumiyama E, et al. Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS\/ERS\/JRS\/ALAT criteria. J Thorac Dis. 2019;11:5247\u201357.","journal-title":"J Thorac Dis"},{"key":"1502_CR65","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/2046-4053-2-71","volume":"2","author":"A Huguet","year":"2013","unstructured":"Huguet A, Hayden JA, Stinson J, et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Syst Rev. 2013;2:71.","journal-title":"Syst Rev"},{"key":"1502_CR66","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","volume":"365","author":"L Richeldi","year":"2011","unstructured":"Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079\u201387.","journal-title":"N Engl J Med"},{"key":"1502_CR67","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"1502_CR68","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1183\/09031936.06.00114004","volume":"27","author":"D Kim","year":"2006","unstructured":"Kim D, Park J, Park B, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27:143\u201350.","journal-title":"Eur Respir J"},{"key":"1502_CR69","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1183\/09031936.00159709","volume":"37","author":"JW Song","year":"2011","unstructured":"Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37:356\u201363.","journal-title":"Eur Respir J"},{"key":"1502_CR70","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/bmjopen-2013-002971","volume":"3","author":"Y Usui","year":"2013","unstructured":"Usui Y, Kaga A, Sakai F, et al. A cohort study of mortality predictors in patients with acute exacerbation of chronic fibrosing interstitial pneumonia. BMJ Open. 2013;3:31.","journal-title":"BMJ Open"},{"key":"1502_CR71","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/crj.12631","volume":"12","author":"M Qiu","year":"2018","unstructured":"Qiu M, Chen Y, Ye Q. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Clin Respir J. 2018;12:1084\u201392.","journal-title":"Clin Respir J"},{"key":"1502_CR72","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/1687-8426.145721","volume":"8","author":"MA Farrag","year":"2014","unstructured":"Farrag MA, El-Sayed AM, Mohammed RM, et al. Evaluation of carbon monoxide diffusing capacity as an early detection of pulmonary involvement in rheumatoid arthritis patients without respiratory symptoms. Egypt J Bronchology. 2014;8:167.","journal-title":"Egypt J Bronchology"},{"key":"1502_CR73","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.semarthrit.2018.10.010","volume":"48","author":"A Young","year":"2019","unstructured":"Young A, Nagaraja V, Basilious M, et al. Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. Semin Arthritis Rheum. 2019;48:1059\u201367.","journal-title":"Semin Arthritis Rheum"},{"key":"1502_CR74","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1183\/09031936.00115511","volume":"40","author":"EP Judge","year":"2012","unstructured":"Judge EP, Fabre A, Adamali HI, et al. Acute exacerbation and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J. 2012;40:93\u2013100.","journal-title":"Eur Respir J"},{"key":"1502_CR75","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","volume":"184","author":"RM du Bois","year":"2011","unstructured":"du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184:1382\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"1502_CR76","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1164\/rccm.201010-1752OC","volume":"183","author":"SC Wootton","year":"2011","unstructured":"Wootton SC, Kim DS, Kondoh Y, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:1698\u2013702.","journal-title":"Am J Respir Crit Care Med"},{"key":"1502_CR77","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","volume":"1","author":"JS Lee","year":"2013","unstructured":"Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1:369\u201376.","journal-title":"Lancet Respir Med"},{"key":"1502_CR78","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","volume":"113","author":"L Richeldi","year":"2016","unstructured":"Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. Respir Med. 2016;113:74\u20139.","journal-title":"Respir Med"},{"key":"1502_CR79","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718\u201327.","journal-title":"N Engl J Med"},{"key":"1502_CR80","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1378\/chest.14-2746","volume":"148","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Taniguchi H, Kondoh Y, et al. Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2015;148:436\u201343.","journal-title":"Chest"},{"key":"1502_CR81","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1056\/NEJM200005043421806","volume":"342","author":"LB Ware","year":"2000","unstructured":"Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334\u201349.","journal-title":"N Engl J Med"},{"key":"1502_CR82","doi-asserted-by":"publisher","first-page":"e035420","DOI":"10.1136\/bmjopen-2019-035420","volume":"10","author":"H Kamiya","year":"2020","unstructured":"Kamiya H, Panlaqui OM. Systematic review and meta-analysis of prognostic factors of acute exacerbation of idiopathic pulmonary fibrosis. BMJ Open. 2020;10:e035420.","journal-title":"BMJ Open"},{"key":"1502_CR83","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.rmed.2016.07.009","volume":"118","author":"AC Zamora","year":"2016","unstructured":"Zamora AC, Hoskote SS, Abascal-Bolado B, et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir Med. 2016;118:39\u201345.","journal-title":"Respir Med"},{"key":"1502_CR84","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1378\/chest.127.6.2019","volume":"127","author":"H-K Lee","year":"2005","unstructured":"Lee H-K, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127:2019\u201327.","journal-title":"Chest"},{"key":"1502_CR85","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1378\/chest.08-2740","volume":"136","author":"H Mukae","year":"2009","unstructured":"Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136:1341\u20137.","journal-title":"Chest"},{"key":"1502_CR86","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/bmj.305.6856.757","volume":"305","author":"GD Smith","year":"1992","unstructured":"Smith GD, Phillips AN. Confounding in epidemiological studies: why \u201cindependent\u201d effects may not be all they seem. BMJ. 1992;305:757\u20139.","journal-title":"BMJ"},{"key":"1502_CR87","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1002\/art.34657","volume":"64","author":"T Gono","year":"2012","unstructured":"Gono T, Kawaguchi Y, Kuwana M, et al. Association of HLA-DRB1*0101\/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthrits Rheum. 2012;64:3736\u201340.","journal-title":"Arthrits Rheum"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01502-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-021-01502-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01502-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T22:04:21Z","timestamp":1620252261000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-021-01502-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1502"],"URL":"https:\/\/doi.org\/10.1186\/s12890-021-01502-w","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"30 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"These were waived as this study was only based on the summary result of previously published articles and individual patient data was not obtained or accessed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}